Clinical Trial: A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07285291) titled 'A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders' on Dec. 03.

Brief Summary: A phase 3, randomized, placebo-controlled, double-blind, phosphate binder-combination study of TS-172 in hyperphosphatemia patients on hemodialysis

Study Start Date: Jan. 05, 2026

Study Type: INTERVENTIONAL

Condition: Hyperphosphatemia Patients on Hemodialysis

Intervention: DRUG: TS-172 20~60 mg/day

oral administration of TS-172 20~60 mg/day

DRUG: Placebo

oral administration of placebo

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Taisho Pharmaceutical Co., Ltd.

Disclaimer: Curated by HT Syndicatio...